Results 11 to 20 of about 11,211 (144)

Trust, but Verify: Translating Dosing Evidence to Understudied Populations in Low- and Middle-Income Countries. [PDF]

Clin Pharmacol Ther
Drug dosing recommendations derived from healthy volunteers and selected preregistration populations may not translate reliably to physiologically distinct or understudied groups, particularly in low‐ and middle‐income countries. Using a metformin–dolutegravir drug interaction study and colistin pharmacokinetic study from South Africa, we illustrate ...
van Rensburg R, Pillay-Fuentes Lorente V, Decloedt E.   +2 more
europepmc   +2 more sources

Dolutegravir [PDF]

Hospital Pharmacy, 2014
Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing ...
Cada, Dennis J, Levien, Terri L, Baker, Danial E   +2 more
openaire   +3 more sources

The risk of hyperglycaemia associated with the use of dolutegravir among adults living with HIV in Kampala, Uganda: a case-control study

The Lancet Global Health, 2022
Background: Emerging evidence suggests a possible association between hyperglycaemia and use of dolutegravir, a preferred first-line antiretroviral agent in sub-Saharan Africa.
Daphine Namara, MBChB, Jeremy I Schwartz, MD, Andrew K Tusubira, MPH, Willi McFarland, ProfMD, Caroline Birungi, MMed, Fred C Semitala, MMed, Martin Muddu, MMed   +6 more
doaj   +1 more source

Efficacy and Durability of Dolutegravir- or Darunavir-Based Regimens in ART-Naïve AIDS- or Late-Presenting HIV-Infected Patients

Viruses, 2023
Background: Since limited data are available, we aimed to compare the efficacy and durability of dolutegravir and darunavir in advanced naïve patients. Methods: Retrospective multicenter study including AIDS- or late-presenting (def.
Massimiliano Fabbiani, Melissa Masini, Barbara Rossetti, Arturo Ciccullo, Vanni Borghi, Filippo Lagi, Amedeo Capetti, Manuela Colafigli, Francesca Panza, Gianmaria Baldin, Cristina Mussini, Gaetana Sterrantino, Damiano Farinacci, Francesca Montagnani, Mario Tumbarello, Simona Di Giambenedetto   +15 more
doaj   +1 more source

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

HIV Research & Clinical Practice, 2021
Background: GEMINI-1 and GEMINI-2 (ClinicalTrials.gov, NCT02831673 and NCT02831764, respectively) are double-blind, multicenter, phase III studies that demonstrated the non-inferiority of once-daily dolutegravir + lamivudine to dolutegravir + tenofovir ...
Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk   +11 more
doaj   +1 more source

Effects of Trimethoprim on Three Previously Proposed Putative Biomarkers for OCT2/MATE-Mediated Renal Drug-Drug Interactions in Healthy Volunteers. [PDF]

Clin Pharmacol Ther
Regulatory agencies request the assessment of the potential of new drugs to cause transporter‐mediated drug‐drug interactions (DDI). This assessment can be improved by integrating endogenous biomarkers during drug development. Regarding the renal excretion of drugs such as metformin, the organic cation transporter (OCT) 2 and multidrug and toxin ...
Picurová J, Müller F, Auge D, König J, Fromm MF, Gessner A.   +5 more
europepmc   +2 more sources

Pro-Inflammatory Interactions of Dolutegravir with Human Neutrophils in an In Vitro Study

Molecules, 2022
There is increasing awareness of an association between the uptake of the HIV integrase inhibitor, dolutegravir, in first-line antiretroviral regimens with unusual weight gain and development of the metabolic syndrome, particularly in African women ...
Annette J. Theron, Ronald Anderson, Morris Madzime, Theresa M. Rossouw, Helen C. Steel, Pieter W. A. Meyer, Moloko C. Cholo, Luyanda L. I. Kwofie, Charles Feldman, Gregory R. Tintinger   +9 more
doaj   +1 more source

Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

BMC Infectious Diseases, 2019
Background Direct comparisons between lamivudine plus bPIs and lamivudine plus dolutegravir as maintenance strategies in virologically-suppressed HIV positive patients are lacking.
Alberto Borghetti, Francesca Lombardi, Roberta Gagliardini, Gianmaria Baldin, Arturo Ciccullo, Davide Moschese, Arianna Emiliozzi, Simone Belmonti, Silvia Lamonica, Francesca Montagnani, Elena Visconti, Andrea De Luca, Simona Di Giambenedetto   +12 more
doaj   +1 more source

Real-World Experience With Lenacapavir and/or Fostemsavir as Emerging Therapies for the Management of Multidrug-Resistant HIV-1 in Southeastern France. [PDF]

J Med Virol
ABSTRACT Lenacapavir and fostemsavir, two recently approved anti‐HIV‐1 agents, are promising options for people with difficult‐to‐treat HIV; however, real‐world data remain limited. This study aimed to describe the epidemiological, clinical, and virological profiles of people receiving combination antiretroviral regimens, including lenacapavir and/or ...
Boujamline S, Boschi C, Bes-Barlandier H, Tomei C, Menard A, Mokhtari S, Ravaux I, Belkhir Y, Neant N, Solas C, Colson P, Million M.   +11 more
europepmc   +2 more sources

Experience of dolutegravir in HIV-infected treatment-naive patients from a tertiary care University Hospital in Ireland

SAGE Open Medicine, 2016
Objective: Dolutegravir, an HIV integrase inhibitor, is a relatively new treatment option. To assess the tolerability, side effects, and time to viral decline to non-detectable in patients newly started on dolutegravir. Methods: Retrospective health care
Sarmad Waqas, Mairead O’Connor, Ciara Levey, Paddy Mallon, Gerard Sheehan, Anjali Patel, Gordana Avramovic, John S Lambert   +7 more
doaj   +1 more source